Inozyme Pharma, Inc. (INZY) financial statements (2022 and earlier)

Company profile

Business Address 321 SUMMER STREET
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 147,697
Cash and cash equivalents 28,040
Short-term investments 119,657
Receivables 155
Prepaid expense 2,323
Other undisclosed current assets 804
Total current assets: 150,979
Noncurrent Assets
Property, plant and equipment 2,648
Long-term investments and receivables 12,199
Long-term investments 12,199
Prepaid expense 3,183
Restricted cash and investments 354
Total noncurrent assets: 18,384
TOTAL ASSETS: 169,363
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 9,973
Accounts payable 3,069
Accrued liabilities 6,904
Total current liabilities: 9,973
Noncurrent Liabilities
Other undisclosed noncurrent liabilities 1,287
Total noncurrent liabilities: 1,287
Total liabilities: 11,260
Stockholders' equity
Stockholders' equity attributable to parent 158,103
Common stock 2
Additional paid in capital 249,175
Accumulated other comprehensive income 2
Accumulated deficit (91,076)
Total stockholders' equity: 158,103
TOTAL LIABILITIES AND EQUITY: 169,363

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
Operating expenses (57,041)
Operating loss: (57,041)
Nonoperating income 617
Investment income, nonoperating 370
Other nonoperating income 247
Net loss available to common stockholders, diluted: (56,424)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
Net loss: (56,424)
Other comprehensive loss (3)
Comprehensive loss, net of tax, attributable to parent: (56,427)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: